- Location
cell lung cancer
"-
Survival Among People with Lung Cancer Has Been Better for Women Than Men
Mar 5, 2014Survival among people with lung cancer has been better for women than men, and the findings of a recent study indicate that female hormones may be a factor in this difference. The combination of estrogen plus progesterone and the use of ...
-
Incyte Has Entered Into a Agreement with Merck Through a Merck Subsidiary
Feb 14, 2014Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 ...
Tags: collaboration agreement, Incyte's oral indoleamine dioxygenase-1, IDO1
-
Etoposide Plus Cisplatin Remains The Gold Standard Regimen for Patients
Jan 24, 2014Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy (AHTRT), remains the gold standard regimen for patients with limited-stage small-cell lung cancer (SCLC), Japanese researchers say. The phase ...
-
Pfizer Has Secured Regular Approval From The Us Food and Drug Administration (FDA)
Nov 25, 2013Pfizer has secured regular approval from the US Food and Drug Administration (FDA) for its Xalkori (crizotinib) capsules to treat patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). The approval was based on ...
-
Boehringer Ingelheim Has Submitted a Marketing Authorisation Application to EMA
Oct 16, 2013Boehringer Ingelheim has submitted a marketing authorisation application to the European Medicines Agency (EMA) for the approval of its oral triple angiokinase inhibitor nintedanib. Nintedanib to be used in combination with docetaxel is ...
Tags: Boehringer Ingelheim, Lung Cancer
-
NovaRx Will Present The Results From The Phase III Trial
Sep 27, 2013US-based biopharmaceutical company NovaRx will present the results from the Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer at the European Society for Medical Oncology (ESMO) ...
Tags: Novarx, Therapeutic Vaccine Trial
-
Cell Signaling Technology Has Presented a Specific HER3 Rabbit Monoclonal Antibody
Aug 30, 2013Cell Signaling Technology has presented a specific HER3 rabbit monoclonal antibody (mAb) for researchers studying HER2-mediated breast, lung and ovarian tumors. The company has introduced this product with the recent need for HER3 in HER2 ...
-
Sagent Pharmaceuticals Has Introduced an Antineoplastic Agent
Aug 2, 2013Specialty pharmaceutical company Sagent Pharmaceuticals has introduced an antineoplastic agent, Docetaxel Injection Concentrate, in three preservative-free vial presentations. Designed to help reduce medication errors, the product ...
Tags: Sagent, Medicine errors
-
FDA Has Cleared Gilotrif as a New Medication for Patients with Late Stage NSCLC
Jul 16, 2013The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...
Tags: FDA, Lung Cancer Therapy, Medicine
-
Genentech and Astellas Pharma US Announced That FDA Has Cleared Tarceva
May 17, 2013Roche Group member Genentech and Astellas Pharma US announced that the US Food and Drug Administration (FDA) has cleared Tarceva (erlotinib). The tablets are used for the initial treatment of people with metastatic non-small cell lung ...
Tags: FDA, Tarceva Tablets, Astellas Pharma
-
MolecularMD Has Obtained a License in Non-Small Cell Lung Cancer Patients
Jan 30, 2013MolecularMD has obtained an exclusive license to LKB1 for diagnostic, prognostic and predictive uses in non-small cell lung cancer patients. The Dana-Farber Cancer Institute, the Massachusetts General Hospital, the University of North ...
-
Cancer Patients Will Be Able to Receive Modern Radiosurgery Treatments
Jan 18, 2013Cancer patients in the north-east of England will be able to receive modern radiosurgery treatments without having to travel outside the region since the Northern Centre for Cancer Care (NCCC) in Newcastle –upon-Tyne announced that it ...
Tags: Cancer patients, NCCC, TrueBeam STx, medical linear accelerators
-
The USFDA Has Accepted for Filing Astellas Pharma's Supplemental New Drug Application
Jan 18, 2013The USFDA has accepted for filing Astellas Pharma's supplemental new drug application (sNDA) for Tarceva (erlotinib) tablets for a genetically distinct form of advanced lung cancer. Astellas is seeking approval to use Tarceva as the ...
-
Clarient Has Entered Into an Agreement for Lung Cancer From Insight Genetics
Dec 18, 2012Clarient Diagnostic Services, a GE Healthcare company, has entered into an agreement to license genomic biomarker for lung cancer from Insight Genetics. AS per the agreement, Clarient intends to develop and assess the performance ...
Tags: Lung Cancer, cooperation, medical technology
-
Astellas Pharma US Is Seeking FDA Approval
Dec 14, 2012Astellas Pharma US is seeking FDA approval for Tarceva tablets to treat non-small cell lung cancer patients (NSCLC) with tumors containing epidermal growth factor receptor (EGFR) that triggers mutations. The company submitted a ...
Related Products
-
High Purity Afatinib CAS 850140-72-6 Afatinib Powder for Non-Small Cell Lung Cancer
-
Pharmaceutical Raw Material Ibrutinib CAS 936563-96-1 White Powder for Non-Small Cell Lung Cancer
-
Erlotinib Hydrochloride Tablet 100mg-Nsclc (non-small cell lung cancer)
-
ISO Certified Reference Material Purity Degree 99% CAS No. 122111-03-9 Gemcitabine HCl
-
ISO Certified Reference Material Gemcitabine Purity Degree 99% CAS No. 95058-81-4
